Meitav Investment House’s NeuroSense Therapeutics NRSN Stock Holding History

Meitav Investment House’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,000	Closed	-$30.2K	–	329
2026 Q1	$30.2K	Hold	2,000	–	–	﹤0.01%	231
2025 Q4	$30.8K	Hold	2,000	–	–	﹤0.01%	241
2025 Q3	$50K	Hold	2,000	–	–	﹤0.01%	236
2025 Q2	$75.6K	Hold	2,000	–	–	﹤0.01%	217
2025 Q1	$37.2K	Hold	2,000	–	–	﹤0.01%	216
2024 Q4	$48K	Hold	2,000	–	–	﹤0.01%	221
2024 Q3	$50.8K	Hold	2,000	–	–	﹤0.01%	227
2024 Q2	$44.8K	Sell	2,000 -500	-20%	-$12.7K	﹤0.01%	221
2024 Q1	$91K	Sell	2,500 -2,250	-47%	-$60.6K	﹤0.01%	229
2023 Q4	$74.6K	Hold	4,750	–	–	﹤0.01%	333
2023 Q3	$67.5K	Hold	4,750	–	–	﹤0.01%	332
2023 Q2	$142K	Hold	4,750	–	–	﹤0.01%	370
2023 Q1	$193K	Buy	+4,750	New	+$158K	﹤0.01%	348

Other funds holding NRSN

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

IAA

Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return

YAG

Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Meitav Investment House's NRSN Position: Q2 2026 in Review

Meitav Investment House sold out of NeuroSense Therapeutics (NRSN) in Q2 2026, closing a stake of 2,000 shares — an estimated $30.2K sold.

Meitav Investment House first reported a position in NRSN in Q1 2023 and held it in 13 quarters. The position peaked at $193K in Q1 2023. 12 funds tracked by Wall St. Rank hold NRSN as of Q2 2026.

Meitav Investment House reported no remaining NeuroSense Therapeutics position as of Q2 2026 after selling out during the quarter.
Meitav Investment House sold 2,000 NeuroSense Therapeutics shares in Q2 2026, an estimated $30.2K.
Meitav Investment House first reported a position in NeuroSense Therapeutics in Q1 2023 and held it in 13 quarters.
Meitav Investment House's NeuroSense Therapeutics position peaked at $193K in Q1 2023.
12 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2026.

Based on Meitav Investment House's 13F filing for Q2 2026, filed 20 Jul 2026.